Cohort Study of the Impact of Time to Antibiotic Administration on Mortality in Patients with Febrile Neutropenia
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The time to antibiotic administration (TTA) has been proposed as a quality-of-care measure in febrile neutropenia (FN); however, few data regarding the impact of the TTA on the mortality of adult cancer patients with FN are available. The objective of this study was to determine whether the TTA is a predictor of mortality in adult cancer patients with FN. A prospective cohort study of all consecutive cases of FN, evaluated from October 2009 to August 2011, at a single tertiary referral hospital in southern Brazil was performed. The TTA was assessed as a predictive factor for mortality within 28 days of FN onset using the Cox proportional hazards model. Kaplan-Meier curves were used for an assessment of the mortality rates according to different TTAs; the log-rank test was used for between-group comparisons. In total, 307 cases of FN (169 subjects) were evaluated. During the study period, there were 29 deaths. In a Cox regression analysis, the TTA was independently associated with mortality within 28 days (hazard ratio [HR], 1.18; 95% confidence interval [CI], 1.10 to 1.26); each increase of 1 h in the TTA raised the risk of mortality within 28 days by 18%. Patients with FN episodes with a TTA of ≤30 min had lower 28-day mortality rates than those with a TTA of between 31 min and 60 min (3.0% versus 18.1%; log-rank P = 0.0002). Early antibiotic administration was associated with higher survival rates in the context of FN. Efforts should be made to ensure that FN patients receive effective antibiotic therapy as soon as possible. A target of 30 min to the TTA should be adopted for cancer patients with FN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 1×
“The time to antibiotic administration (TTA) is a well-recognized determinant of mortality in patients with severe sepsis or septic shock (5).”
BackgroundClinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
Kuderer, N. M., Dale, D. C., Crawford, J., Cosler, L. E., & Lyman, G. H. (2006) · Cancer · doi:10.1002/cncr.21847 · Cited by 1,176
Klastersky, J., Paesmans, M., Rubenstein, E. B., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., Rolston, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3038 · Cited by 1,171 · cited 1×
“The Multinational Association for Supportive Care in Cancer (MASCC) risk index score (11) was applied at the onset of fever to determine the risk for serious complications during FN; episodes were classified as high risk if the score was 21 points and as low risk if the score was 21 points.”
MethodGaieski, D. F., Mikkelsen, M. E., Band, R. A., Pines, J. M., Massone, R., Furia, F. F., Shofer, F. S., & Goyal, M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181cc4824 · Cited by 970 · cited 1×
“(13) showed a relative risk reduction of mortality by 70% for nonneutropenic intensive care patients with severe sepsis and septic shock treated with an appropriate antibiotic within 1 h of triage compared with that for those with a TTA of 1 h (P 0.”
BackgroundManagement of Fever in Neutropenic Patients with Different Risks of Complications
Klastersky, J. (2004) · Clinical Infectious Diseases · doi:10.1086/383050 · Cited by 287 · cited 8×
“9 (31.0) 155 (55.7) 0.39 (0.17–0.86) 0.02 ANC at the time of FN diagnosis (median [IQR]) (cells/mm3) 130 (260) 130 (260) 1.00 (0.99–1.00) 0.37 ANC 100 cells/mm3 at the time of FN diagnosis (no.”
BackgroundInfluentialSurvival in neutropenic patients with severe sepsis or septic shock*
Legrand, M., Max, A., Peigne, V., Mariotte, E., Canet, E., Debrumetz, A., Lemiale, V., Seguin, A., Darmon, M., Schlemmer, B., et al. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31822b50c2 · Cited by 281
Rolston, K. V. I. (2005) · Clinical Infectious Diseases · doi:10.1086/427331 · Cited by 174 · cited 1×
“Current guidelines for treatment of sepsis and FN (6, 7), based mainly on studies involving immunocompetent subjects, recommend administration of broad-spectrum -lactam antibiotic monotherapy with antipseudomonal activity within 1 h after the onset of fever in the neutropenic patients; furthermore, many oncology cente…”
BackgroundFletcher, M., Hodgkiss, H., Zhang, S., Browning, R., Hadden, C., Hoffman, T., Winick, N., & McCavit, T. L. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24485 · Cited by 148 · cited 1×
“(14) found that a TTA of 60 min, compared with a TTA of 61 min to 120 min, was associated with a lower incidence of a composite endpoint that included in-hospital mortality, intensive care unit admission, and fluid resuscitation of 40 ml/kg within 24 h of presentation in pediatric FN patients.”
BackgroundHamandi, B., Holbrook, A. M., Humar, A., Brunton, J., Papadimitropoulos, E., Wong, G. G., & Thabane, L. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02664.x · Cited by 68 · cited 1×
“(15), there was a significant association between increasing TTA (24-h increments) and increased hospital mortality rates in solid-organ transplant patients.”
BackgroundMcCavit, T. L., & Winick, N. J. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23148 · Cited by 49
Amado, V. M., Vilela, G. P., Queiroz, A. R. F. B., & Amaral, A. C. K.-B. (2010) · Journal of Critical Care · doi:10.1016/j.jcrc.2010.05.034 · Cited by 44 · cited 1×
“Current guidelines for treatment of sepsis and FN (6, 7), based mainly on studies involving immunocompetent subjects, recommend administration of broad-spectrum -lactam antibiotic monotherapy with antipseudomonal activity within 1 h after the onset of fever in the neutropenic patients; furthermore, many oncology cente…”
BackgroundHaskamp, A. C., & Snyder, S. (2008) · Journal of Pediatric Oncology Nursing · doi:10.1177/1043454208319971 · Cited by 42
Burry, E., Punnett, A., Mehta, A., Thull‐Freedman, J. D., Robinson, L. A., & Gupta, S. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23418 · Cited by 31
van Vliet, M., Potting, C. M. J., Sturm, P., Donnelly, J. P., & Blijlevens, N. M. A. (2011) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2011.01264.x · Cited by 14 · cited 1×
“Duration of neutropenia (median [IQR]) (days) 8 (16) 9.”
Cited by
Taplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6211 · Cited by 426
Metadata
- Authors
- Rosa, R. G., & Goldani, L. Z.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-07
- Volume
- 58
- Issue
- 7
- Pages
- 3799-3803
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2114201476
- Cited by
- 177
- References
- 19
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.